Study of Epidemiological, Clinical, Molecular, and Treatment Data in Adults with Prolymphocytic T-Cell Leukemia

What this Trial Is About

Prolymphocytic T leukemia is a rare and aggressive blood cancer mainly affecting older adults. It involves changes in chromosome 14 related to T cell receptors and shows activation of specific molecular pathways. Patients often have a poor prognosis with limited response to standard chemotherapy. Treatments like alemtuzumab and stem cell transplants can extend survival, but new targeted therapies are needed for those who cannot undergo intensive treatment. This observational study aims to better understand and manage Prolymphocytic T leukemia by examining its clinical, molecular, and treatment characteristics. This study collects detailed epidemiological, clinical, molecular, and therapeutic data on Prolymphocytic T leukemia through both prospective and retrospective observations. Researchers will analyze biological samples such as bone marrow and blood cells using flow cytometry and karyotyping at diagnosis and relapse. The study focuses on the diseases molecular features and response to treatments to improve patient care. Participants will be followed for an average of three years, with assessments at diagnosis and relapse to gather clinical and biological data. Researchers will monitor disease characteristics using laboratory tests and flow cytometry, as well as study survival and treatment outcomes. This long-term observation helps identify factors influencing treatment response and disease progression, supporting improved management strategies for this leukemia.

Observatory of Prolymphocytic Leukemia T